問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberCELC-G-301
NCT Number(ClinicalTrials.gov Identfier)-
Active

2023-03-11 - 2027-03-01

Phase III

Not yet recruiting1

Recruiting7

ICD-10C50.911

Malignant neoplasm of unspecified site of right female breast

ICD-10C50.912

Malignant neoplasm of unspecified site of left female breast

ICD-10C50.919

Malignant neoplasm of unspecified site of unspecified female breast

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9174.9

Malignant neoplasm of female breast, unspecified

-

  • Trial Applicant

    TAIWAN PSI HEALTH DEVELOPMENT COMPANY LIMITED

  • Sponsor

    -

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/05/13

Investigators and Locations

Principal Investigator Ming-Feng Hou Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator 陳守棟 Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator JO-PAI CHEN Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Kuo-Ting Lee

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator TSU-YI CHAO Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Ling-Ming Tseng Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Liang-Chih Liu Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator YEN-SHEN LU

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Study Contacts

- -

Condition/Disease

-

Objectives

-

Test Drug

-

Active Ingredient

-

Dosage Form

-

Dosage

-

Endpoints

-

Inclution Criteria

-

Exclusion Criteria

-

The Estimated Number of Participants

  • Taiwan

    34 participants

  • Global

    701 participants